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A novel assay for the measurement of activated thrombin activatable fibrinolysis
inhibitor (TAFIa) activity
Importance of Project
The proper functioning of the circulatory system relies on a balance between the
coagulation and fibrinolysis cascades. Blood clot formation at a site of vascular injury
prevents excessive blood loss and allows cellular repair, while subsequent clot dissolution
ensures that blood circulation is restored. Thrombin activatable fibrinolysis inhibitor
(TAFI) is a human plasma zymogen that plays an important role in maintaining this
balance. Activated TAFI (TAFIa), a basic carboxypeptidase enzyme, attenuates the
fibrinolytic positive feedback cascade by cleaving carboxyl-terminal lysine residues in
partially-degraded fibrin. TAFI is activated by proteolytic cleavage in response to
activation of coagulation. Since excessive blood loss, characteristic of hemophilia, as
well as thrombotic events, as seen in heart attacks and strokes, are related to an imbalance
in these cascades, the study of TAFI is of great importance to the medical field. The role
of TAFI in wound healing, inflammation and cancer cell metastasis are additional areas
of current research.
Existing State of Knowledge
The ability to accurately measure TAFIa activity is pivotal to understanding the
function and regulation of TAFI in biological systems. Various methods are available for
the detection of TAFIa, including the immunological method ELISA, enzymological
assays and functional assays. Enzymological assays exploit the carboxypeptidase activity
of TAFIa for cleavage of carboxyl-terminal arginine and lysine residues from small
substrates containing a chromophore. This is advantageous in comparison to ELISA,
since only TAFIa fragments are measured, not the zymogen nor inactive fragments of
TAFIa. Two current classes of substrates for the enzymatic study of TAFIa include the
hippuryl-arginine/lysine and anisylazoformyl-arginine/lysine assays, which possess
various pitfalls. For instance, turbidity resulting from blood clot formation interferes with
reading the absorbance of a chromogenic substrate or product in the assay. Additionally,
low concentrations of TAFIa cannot be detected as the assays are not particularly
sensitive and the activity of TAFIa cannot be monitored in real time. In comparison, a

functional TAFIa assay designed by Kim and coworkers is very sensitive, allowing
measurement of picomolar concentrations of TAFIa in plasma. It also utilizes
fluorescence detection, which avoids the issue of turbidity interference for absorbance
measurements. Despite these advantages, the numerous purified protein components that
must be prepared for this assay may lead to inconsistent results. Moreover, TAFIa
activity cannot be measured in real time using this assay.
Research Question
Thus, the focus of my project is to design and optimize a novel fluorescence assay
for the measurement of TAFIa activity in real time, with increased sensitivity compared
to current methods.
Methodology
Baby hamster kidney (BHK) cells expressing recombinant poly-histidine tagged
wild type TAFI have been cultured, followed by protein purification, to acquire pure wild
type TAFI protein. Complete activation of TAFI to TAFIa is achieved with a serine
protease enzyme, thrombin (IIa), in complex with its cofactor thrombomodulin (TM).
The synthetic substrate designed for the assay is a peptide composed of four amino acids
(GAGR) modified with an amino-terminal tetramethylrhodamine (TAMRA) fluorophore.
An anionic quencher, Evan’s Blue dye, interacts electrostatically with the positively
charged carboxyl-terminal arginine in the substrate, quenching TAMRA’s fluorescence.
Arginine cleavage by TAFIa releases the associated quencher resulting in a measurable
increase in fluorescence, indicative of TAFIa activity.
Findings
Thus far, my research has shown that the cleavage of the TAMRA-GAGR peptide
by TAFIa is measurable as an increase in fluorescence intensity and thus, in principle, the
assay is a promising means of measuring TAFIa activity. Optimization of the assay will
be conducted in terms of the relative concentrations of fluorescent substrate and
quencher, as will development of a TAFIa standard curve. The sensitivity of the assay
will be explored further, which is important due to the low TAFIa concentration (20 –
100 pmol/L) present in human plasma. This assay will be applied to measuring TAFIa

activity natively present in plasma samples and total TAFI concentrations (after
activation by IIa-TM) present in plasma, tissue or secreted by cells. It will also be applied
to routine characterization of TAFI, such as after purification of recombinant variants.
The ability to study TAFIa generation in real time within clots will allow further insight
into the regulation of TAFIa elaboration in response to thrombogenic stimuli. There is
also potential to identify individuals at risk for hematological or vascular diseases based
on variation in plasma TAFI levels or altered TAFIa generation and function.
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